
NEWS
Why CMC Matters in Biologics Development
Biopharmaceutical innovators developing recombinant proteins, nanobodies, plasmid DNA, vaccines, mRNA, and circRNA face a recurring set of obstacles: low yields and stability issues in mammalian

Biopharmaceutical innovators developing recombinant proteins, nanobodies, plasmid DNA, vaccines, mRNA, and circRNA face a recurring set of obstacles: low yields and stability issues in mammalian
